PIK3CA and cancer: In conclusion, our findings demonstrate that the subcellular localization of FOXO3a during the treatment with PI3K inhibitors might be a valuable biomarker for selecting patients with PIK3CA-mutant cancers who might show clinical benefits upon the combination therapy with inhibitors of PI3K and autophagy.